Enzo Biochem Announces Presentation at Lazard Capital Markets Third Annual Life Sciences Conference

Enzo Biochem, a leading biotechnology company, announced that Barry Weiner, President, will make a presentation at the Lazard Capital Markets Third Annual Life Sciences Conference on November 28, 2006. The company is engaged in the research, development, and manufacture of innovative healthcare products based on molecular biology and genetic engineering techniques. Their proprietary labeling and detection products are sold worldwide, and they are in various stages of clinical evaluation for several gene therapies, including HIV-1 infection and immune regulation medicines.

Key Takeaways:

• Enzo Biochem is a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies.
• The company will make a presentation at the Lazard Capital Markets Third Annual Life Sciences Conference on November 28, 2006.
• Enzo Biochem has developed proprietary labeling and detection products for gene sequencing and genetic analysis sold worldwide.
• The company's therapeutic division is in various stages of clinical evaluation for gene medicines, including HIV-1 infection and immune regulation medicines.
• Pre-clinical research is being conducted on several candidate compounds for treating various conditions, including osteoporosis and fractures.
• Enzo Biochem owns or licenses over 200 patents worldwide, including a patent for correcting point mutations in genetic material.

Statistics:

• November 28, 2006: Date of Enzo Biochem's presentation at the Lazard Capital Markets Third Annual Life Sciences Conference.
• 2006: Year in which Enzo Biochem announced their presentation at the Lazard Capital Markets Third Annual Life Sciences Conference.
• 4:30P.M. (E.T.): Time of Enzo Biochem's presentation at the Lazard Capital Markets Third Annual Life Sciences Conference.
• Over 200: Number of patents owned or licensed by Enzo Biochem worldwide.
• Various: Number of stages to which Enzo Biochem's therapeutic division is progressing with clinical evaluation.

Sources:

• "Enzo Biochem, Inc. Announces Presentation at Lazard Capital Markets Third Annual Life Sciences Conference" by Enzo Biochem, Inc.
• The Securities Act of 1933, as amended and The Securities Exchange Act of 1934, as amended.